The development of immunomodulatory therapies for multiple sclerosis (MS) has had
significant impact in altering the natural history of the disease. Although these agents reduce …

Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central
nervous system, with highly variable clinical course that most typically exhibits a relapsing …

The range of symptoms which occur in multiple sclerosis (MS) can have disabling functional
consequences for patients and lead to significant reductions in their quality of life. MS …

Multiple sclerosis (MS) is a disease with a wide-ranging impact on physical functioning.
Although pharmacotherapy plays an indispensable role in the management of MS …

Although the armamentarium of disease-modifying therapies has expanded greatly, a more
significant impact on quality of life for patients with multiple sclerosis (MS) remains via …

Overview. Clinical types of MS. MS is a chronic recurrent inflammatory disorder of the CNS.
The disease results in injury to the myelin sheaths, the oligodendrocytes, and, to a lesser …

Besides immunomodulation and immunosuppression, the specific treatment of symptoms is
an essential component of the overall management of multiple sclerosis (MS). Symptomatic …

Multiple sclerosis (MS) is primarily an autoimmune disease of the central nervous system,
but also encompasses prominent neurodegenerative aspects. A significant proportion of MS …

Multiple sclerosis (MS) is an immunologically mediated disorder in which inflammation and
demyelination of the central nervous system white matter are prominent features, resulting in …

The therapy for multiple sclerosis (MS) has changed dramatically over the past decade.
Several agents have been approved and are now being widely used, and a whole battery of …